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Abstract
The autoantibody-mediated subepidermal blistering skin disease bullous pemphigoid affects both humans and dogs. We
previously demonstrated that canine bullous pemphigoid patient’s autoantibodies targeted skin basement membrane
component and a 180-kDa keratinocyte protein. We extend our works to partially isolate the cDNA encoding canine bullous
pemphigoid antigen 2 (BPAg2, BP180). Total RNA extracted from a papillomavirus-immortalized canine keratinocyte cell
line and a cultured canine squamous carcinoma cell line SCC 2/88 were used to isolate fragments of cDNA encoding BPAg2
by reverse transcription-PCR and 5P-rapid amplification of cDNA end. The isolated sequence included the 5P-untranslated
region, the entire intracellular, transmembranous, and extracellular NC16A autoantigenic domains, plus a small segment of
the collagenous domain. Sequence analyses of the isolated cDNA showed 87 and 85% identities between canine and human
at the nucleotide sequence and at the deduced amino acid sequence levels, respectively. The canine BPAg2 sequence was
confirmed by a rabbit antibody raised against a 18-amino acid peptide deduced from the canine NC16A nucleotide sequence.
Autoantibodies from canine bullous pemphigoid patients’ sera recognized epitopes within the human NC16A domain. The
cloning of the cDNA encoding this disease-associated protein may allow us to develop a canine model in dissecting the
immunopathologic mechanism underlying bullous pemphigoid. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Bullous pemphigoid (BP) is an autoantibody-medi-
ated subepidermal blistering skin disease character-
ized by IgG antibodies against the skin basement
membrane zone (BMZ) BP antigens (Ags) located
in the upper lamina lucida/hemidesmosome areas
[1^5]. Two major Ags, the intracellular BPAg1
(BP230) and the transmembranous BPAg2 (BP180,
type XVII collagen) are recognized by the patients’
autoantibodies [1^3]. The human BPAg2 consists of
an intracellular domain at its N-terminus, a trans-
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membranous segment, and an extracellular domain
at its C-terminus [4,5]. The extracellular domain of
human BPAg2 is composed of a collagenous domain,
interrupted by 15 minor non-collagenous domains, at
its C-terminus, and £anked by a major 77-amino
acid non-collagenous domain at its N-terminus,
termed NC16A [4]. This NC16A domain, located
immediately C-terminal to the transmembranous seg-
ment, contains a common 14-amino acid antigenic
site for the human BP autoantibodies [6]. Moreover,
the antigenic epitopes of the BPAg2 are tightly clus-
tered within a 45-amino acid stretch located at the
N-terminus of this NC16A segment [7]. Whereas the
pathogenic role of BPAg1 has yet to be determined,
the BPAg2 has been implicated for its pathogenic
role. In a cohort study of 94 BP patients, the pres-
ence of circulating autoantibodies against BPAg2,
but not autoantibodies against BPAg1, correlated
with a poor prognosis [8]. A more direct evidence
supporting the pathogenic role of BPAg2 has been
illustrated in passive transfer experiments conducted
in neonatal BALB/c mice [9^11]. Rabbit antibodies
raised against a recombinant protein containing the
murine equivalent of human NC16A domain bound
to neonatal mouse skin basement membrane and
induced subepidermal blisters [9]. One of the inter-
esting question which remains unanswered by this
passive transfer model, however, is whether the
eosinophil plays a role in the pathogenesis of BP
blister formation [9^11].
Besides a¡ecting human patients, BP also a¡ects
canine patients [12,13]. Like human BP, canine BP is
characterized histopathologically by eosinophil in¢l-
tration in the blister cavity. We have previously dem-
onstrated that canine BP autoantibodies labeled a
BMZ component of both human and canine skin
and recognized a 180-kDa protein (presumably
BPAg2) present in both human and canine keratino-
cyte extracts [13]. The purpose of the current work
was to delineate the cDNA encoding for the canine
BPAg2 antigenic NC16A domain and to identify the
antigenic epitopes recognized by canine BP patients’
autoantibodies. Our hope is that we may be able to
develop a canine animal model of BP, in order to
answer the question whether eosinophil plays a role
in the BP blister formation. We herein demonstrate
that the 77-amino acid sequence of the BPAg2
NC16A domain in canine species shares 58% identity
and 71% homology (identical plus conservatively
substituted amino acids), with that of human. How-
ever, canine BP patients’ autoantibodies share some
immunologic similarities with that of human BP pa-
tients in that they crossreacted with antigenic epitopes
on human NC16A domain that are known to be
recognized by autoantibodies of human BP patients.
2. Materials and methods
2.1. Cell cultures
An immortalized canine keratinocyte cell line was
established from normal dog skin. Dog skin was ob-
tained from a healthy dog and the epidermis was
removed by incubation with enzyme [14]. Dog kera-
tinocytes were grown in the presence of a low calci-
um keratinocyte serum-free medium (Gibco-BRL,
Grand Island, NY) [14]. When the dog keratinocytes
were attached to the Petri dishes, immortalization
was performed by adding papilloma virus as previ-
ously described [15]. The immortalized cells were
con¢rmed to be keratinocytes by demonstrating the
presence of keratin and BPAg2 with indirect immu-
no£uorescence microscopy using antibodies to hu-
man keratin and BPAg2. A canine squamous cell
carcinoma line was obtained from Dr. Rosol (Ohio
State University, Columbus, OH). These cells were
initiated from a canine oral squamous carcinoma cell
line SCC 2/88 [16] and were maintained and subcul-
tured in Williams’ medium E (Gibco-BRL) contain-
ing the following supplements: 10% fetal bovine se-
rum (Gibco-BRL), 10 ng/ml epidermal growth factor
(Gibco-BRL), 0.1 nM cholera toxin (Gibco-BRL),
and 2.0 mM L-glutamine (Gibco-BRL).
2.2. Isolation of cDNA fragments encoding canine
BPAg2
At con£uency, the papillomavirus-immortalized
canine keratinocytes were washed with 1Uphos-
phate-bu¡ered saline (PBS) and placed on ice. The
total RNA was extracted using a standardized solu-
tion RNAzol (TEL-TEST, Friendswood, TX) ac-
cording to the manufacturer’s manual [17]. RNA
was similarly extracted from the SCC 2/88 cells
which has been used by us to clone a cDNA encod-
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ing a canine type VII collagen [18]. One half Wg of
total RNA was used in each reverse transcription
(RT)-PCR reaction using an XL RNA-PCR kit spe-
ci¢cally designed for cDNA cloning (Catalog No.
N808-0205, Perkin-Elmer, Foster City, CA). Brie£y,
the RTs were performed in a 20-Wl solution contain-
ing the RNA in the presence of 5 U of rTth DNA
polymerase XL, 20 pmol 3P-primer, 1.1 mM
Mn(OAc)2, 200 WM each of dATP, dCTP, dGTP,
and dTTP, and RT bu¡er (¢nal concentrations:
30 mM tricine, 75 mM potassium acetate, 10% glyc-
erol, pH 8.5). The RTs were performed at 60‡C for
60 min on a GeneAmp 2400 PCR System (Perkin-
Elmer). The PCR reactions were performed in a
100-Wl solution containing the RT reaction mixture,
plus 20 pmol 5P-primer, 1 mM Mg(OAc)2, 16 Wl XL
RNA chelating bu¡er (stock concentrations: 220
mM tricine, 470 mM potassium acetate, 47% glycer-
ol, 1.5 mM EGTA, pH 8.6). the 40-cycled PCR re-
action was preceded by one cycle of denaturation
(94‡C, 1 min), followed by 20 cycles of 94‡C, 15 s;
65‡C, 3 min 45 s; and by another 20 cycles of 94‡C,
15 s; and 65‡C, 3 min 45 s with 15 s anneal/extension
autoextension according to the manufacturer’s in-
structions. An additional 10 min of extension
(72‡C) was performed after 2 U of Taq polymerase
(Perkin Elmer) was added to the PCR solution for
the purpose of creating the TA hanging. The primer
pairs used in the RT-PCR experiments were designed
to generate overlapping cDNA fragments using the
human BPAg2 cDNA sequence as a guide (Table 1)
[4,19]. When available, newly delineated canine
BPAg2 cDNA sequence will be used to design prim-
ers. To isolate the nucleotide sequence of the non-
coding region at the 5P-end, 5P-RACE was performed
on 0.5 Wg total RNA of canine SCC 2/88 cells, using
a 5P-RACE kit obtained from Gibco-BRL (Version
2, Catalog No. 18374-058) and primer designed from
canine BPAg2 cDNA sequence (Table 1).
2.3. cDNA cloning and sequence analysis
The RT-PCR products, determined to be single
bands by electrophoresis, were ligated into TA clon-
ing vector (Invitrogen, San Diego, CA), according to
the manufacturer’s manual. The ligated constructs
were transformed into INVKFP competent cells (In-
vitrogen) on X-Gal-coated agar plates. The white
colonies were selected for plasmid DNA mini prepa-
rations and the presence of inserts was con¢rmed by
EcoRI endonuclease digestion. The insert-containing
clones were ampli¢ed and puri¢ed and then were
subjected to double-stranded DNA sequencing by
an ABI Prism Model 377 Fluorescence Automated
Sequencer (Perkin-Elmer). The DNA sequence of
each fragment was con¢rmed by four to ¢ve inde-
pendently isolated TA clones. Sequence analyses,
alignments, and amino acid translations were per-
formed using MacVector and AssemblyLIGN soft-
ware (Oxford Molecular, Campbell, CA).
2.4. Northern blot hybridization
Northern blot was performed by a standardized
method [20], using a human cDNA probe encoding
a region of the human BPAg2. Human keratinocyte
Table 1
The sequence-speci¢c primers designed to isolate canine BPAg2 by RT-PCR and 5P-RACE
Clone no. Primer Nucleotide sequence (5P^3P direction) Size (bp)
13 RT-primer TTTGGATCCTGCTGCAGCTGGTGGAA 767
PCR-primer TTCTCACCCTGGTCACCTTTGG
8 RT-primer GAAGAAAAACATGCCCCAGAGTC 593
PCR-primer ATTTTGTCCAGGTCTGCTCCCG
2 RT-primer ACTCAAGTGGAAGCACACGAGG 811
PCR-primer CTCATTCTGGACATTTGTGGTGC
50 RT-primer GGATCGTTGCATCGTAGGTGC 384
PCR-primer AGGTGGAGCCTGGGGAGTTG
Clone 50 encodes the DNA of the 5P-non-coding end is the result of 5P-RACE, using the nesting PCR method.
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total RNA was extracted from a primary normal
human keratinocyte culture as previously described
[14,17]. The human BPAg2 cDNA was obtained by
RT-PCR method to amplify a cDNA reversely tran-
scribed from human keratinocyte RNA as described
in the above section, using the following primer pair:
RT-primer, 5P-TTCTCACCCTGGTCACCTTT-3P ;
PCR-primer, 5P-TCCTGCTGCAGCTGGTGGAA-
3P. The human BPAg2 cDNA was cloned into TA
vector. After the cDNA sequence was veri¢ed by the
method described in the above section, it was then
used as hybridization probe.
2.5. Anti-peptide antibody production
A peptide of 18-amino acids size was generated
from amino acid sequence deduced from the isolated
canine BPAg2 cDNA within the NC16A-equivalent
domain: 5P-SRSNVLLFKEEMQRANKD-3P and
was coupled with KLH at the C-terminus (Sigma-
Genosys, Woodlands, TX). This peptide was puri¢ed
to s 95% purity by HPLC and then was injected
into two rabbits for anti-peptide antibodies (Sigma-
Genosys). Post-immune serum containing high titer
(1:25 000) of antibodies against the peptide as deter-
mined by ELISA was used in the indirect immuno-
£uorescence and immunoblotting studies described
below.
2.6. Indirect immuno£uorescence studies
Indirect immuno£uorescence was performed as
previously described [21]. Six-Wm-thick cryosections
of salt-split normal canine skin were used as sub-
strates [22]. In the studies with human patients’
sera, the incubation of diluted sera was followed by
incubation with £uorescein-conjugated goat anti-hu-
man IgG (Cappel, Durham, NC). In the studies with
rabbit antisera, the incubation of diluted sera was
followed by incubation of £uorescein-conjugated
monoclonal mouse anti-rabbit IgG (Q-chain speci¢c,
Sigma, St. Louis, MO). Normal human serum and
pre-immune rabbit serum at the same dilutions
were used as negative controls. The specimens were
examined under a Olympus BX60 £uorescence
microscope equipped with epi-illumination and pho-
tographed.
2.7. Immunoblotting
Immunoblotting was performed as previously de-
scribed [21] with slight modi¢cations. At con£uency,
the SCC 2/88 cultures were ¢rst washed with
1UPBS. A mammalian culture cell protein extraction
reagent (2 ml/100 mm dish, M-PER, Pierce, Rock-
ford, IL) was added to the cell layer and the cells
were placed on a shaker for 5 min at room temper-
ature. The cell extracts were harvested by scraping
followed by repeated pipetting. The supernatant was
collected by centrifugation at 13 000 rpm (4‡C,
10 min) and stored at 320‡C. The supernatant pro-
teins were mixed with sample bu¡er, boiled, loaded
onto the slots of 4% stacking gel over 6% separating
gel on a mini gel system of polyacrylamide gel elec-
trophoresis (Novex, San Diego, CA), and were ver-
tically separated at a constant voltage (125 V, 2 h),
Table 2
The non-overlapping synthetic peptides containing the entire human extracellular NC16A domain of BPAg2





Fig. 1. The canine BPAg2 molecule: nucleotide and deduced amino acid sequence. The nucleotide sequence of the 5P-end untranslated
region is depicted in the ¢rst line (in lower case letters). The remaining (in capital letters) depicts the nucleotide and the deduced ami-
no acid sequences of the coding region of the partially isolated canine BPAg2. The deduced amino acid sequence included the entire
intracellular domain (amino acids 1^467), the transmembranous segment (underlined, amino acids 468^490), the extracellular NC16A
domain (bracketed by T and T, amino acids 491^567), and small segment of extracellular collagenous domain (partial, amino acids
568^709) (GenBank accession no. AF016649).
C
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under reducing conditions. The proteins were then
horizontally transferred to nitrocellulose membranes
(Bio-Rad, Hercules, CA). After the transfer e⁄ciency
was con¢rmed by Ponceau S stain (Sigma), the mem-
branes were cut into strips, incubated in 5% pow-
dered milk to block non-speci¢c binding sites, and
then incubated with rabbit antisera diluted in 1%
BSA in Tween Tris bu¡er saline (Tris 50 mM,
Fig. 2. Direct comparison of the human (upper line), canine (middle line), and murine (lower line) deduced amino acid sequence of
the intracellular, the transmembranous, and the partial extracellular domain of BPAg2. The transmembranous domain is bracketed by
T and T. The NC16A domain is bracketed by T and T. Two amino acids absent from the murine sequence are denoted by a. One
extra amino acid (G) is noted in the canine sequence in comparing to human sequence (amino acid 108). Extra amino acids are also
noted in the murine sequence (amino acids 108 (G) and 436^443 (RGKGGGAG)). The human and murine sequences were taken di-
rectly from the GenBank database. The canine sequence has the GenBank accession no. AF016649.
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NaCl 145 mM, 0.05% Tween-20, pH 7.5) overnight
at 4‡C. The immunoreactions were completed using a
peroxidase-conjugated goat anti-rabbit IgG (Kirkke-
gaard and Perry, Gaithersburg, MD) and visualized
with 4-chloro-1-naphthol (Bio-Rad).
2.8. ELISA studies
To examine whether autoantibodies from canine
BP patients recognize the same antigenic epitopes
that are recognized by human BP autoantibodies,
ELISA studies [23] were performed with sera from
two canine BP patients (one 6-year-old Weimaraner,
one 2-year-old pit bull) documented by histopathol-
ogy (subepidermal blister with eosinophil in¢ltra-
tion), immunopathology (in vivo-bound IgG deposi-
tion at skin BMZ and circulating IgG anti-BMZ
autoantiboies bound to the epidermal side of salt-
split skin), and immunoblotting (circulating IgG
autoantibodies recognized a 180-kDa epidermal pro-
tein). Four non-overlapped peptides containing the
entire major extracellular antigenic human NC16A
domain were synthesized, puri¢ed by HPLC, and
con¢rmed by mass spectrometry, and then were
used in the studies (Tana Laboratories, Houston,
TX, Table 2). Brie£y, 5-Wg peptides were coated
onto each well in the 96-well plates overnight at
4‡C. The diluted sera from canine BP patients and
control sera (¢ve normal dogs, a dog a¡ected with
epidermolysis bullosa acquisita), and a dog a¡ected
with linear IgA bullous dermatosis) were incubated
with the peptide protein at room temperature for 3 h,
followed by incubation of alkaline phosphatase-
labeled goat anti-dog IgG at room temperature for
2 h. The reactions were visualized with an alkaline
phosphatase substrate (Bio-Rad) and measured OD
as absorbance at 405 nm wave length on an ELISA
reader as previously reported [23].
2.9. Immunoelectron microscopy
Indirect immunoelectron microscopy was per-
formed with a human BP patient’s IgG anti-BPAg2
autoantibodies on salt-split canine skin using a
standardized peroxidase-antiperoxidase method with
some modi¢cations [24^26]. Normal human serum at
the same dilution was used as negative control. The
ultrathin sections (80 nm) were examined under a
Hitachi HU-12A transmission electron microscope
and photographed.
3. Results and discussion
3.1. The canine BPAg2 cDNA and amino acid
sequences share moderate homology to the human
counterpart
Using previously delineated human BPAg2 cDNA
sequence [4], primer sets were designed and utilized
to isolate canine BPAg2 cDNA clones in the coding
region and in the 5P-non-coding region. The double-
stranded nucleotide sequence was determined by au-
Fig. 3. The canine BPAg2 mRNA co-migrates with the human
BPAg2 mRNA. Northern blot analysis of canine SSC 2/88 total
RNA (left lane) with a human BPAg2 cDNA probe identi¢es a
6-kb mRNA (arrow), co-migrating with a 6-kb human keratino-
cyte mRNA (right lane) hybridized with the same cDNA probe.
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tomated DNA sequencing method. The nucleotide
sequence of the canine BPAg2 cDNA was submitted
to GenBank database (accession number BP180
AF016649). The isolated sequence include the 5P-
end of the untranslated region, the entire intracellu-
lar, transmembranous, NC16A domains, plus a small
stretch of the extracellular collagenous domain. The
total number of nucleotides isolated was 2127 in the
coding region and 92 in the 5P-end untranslated re-
gion. Sequence analyses between the isolated canine
coding sequence and the human counterpart show a
87 and 85% identity at the nucleotide and at the
amino acid levels, respectively. The nucleotide se-
quence of the 5P-end of the untranslated region and
the partially isolated coding region and its deduced
amino acid sequence are shown in Fig. 1. A direct
comparison of the deduced amino acid sequence (709
amino acids) of the canine BPAg2 cDNA and the
human and mouse counterparts are depicted in Fig.
2. Interestingly, within the 77 amino acids of the
NC16A domain, the identity between human and
canine sequence is only 58% (Fig. 2), similar to the
identity (57%) between the human and murine se-
quences in this domain [27] (Table 3). The data
here showing the canine amino acid sequence at the
NC16A domain being less conserved than the rest of
the BPAg2 molecule is intriguing. However, this ¢nd-
ing is not unique in canine species. Murine BPAg2
amino acid sequence, for example, shares an 81%
overall identity with that of human [27]. It is also
interesting in noting that the amino acid sequences
of the transmembranous domains are totally identi-
cal in human, dog, and mouse genes (Fig. 2 and
Table 3).
Fig. 4. The canine BPAg2 is localized to the upper skin BMZ. Indirect immuno£uorescence microscopy revealed that a rabbit anti-ca-
nine NC16A peptide antiserum (b), but not the pre-immune serum from the same rabbit (a), labeled the epidermal side of BMZ on
salt-split normal canine skin substrate. Control human anti-BPAg2 autoantibodies (c) and anti-type VII collagen autoantibodies (d) la-
beled the epidermal and dermal sides of canine salt-split skin, respectively. Arrows indicate the binding of antibodies to skin BMZ.
Scale bar: 25 Wm (a^d).
Table 3
Percent amino acid identity of BPAg2 domains in human/dog and human/mouse
BPAg2 domains Total amino acids in humans Percent identitya
Human/dog Human/mouse
Intracellular 466 88% 85%
Transmembrane 23 100% 100%
NC16A 77 58% 57%
aIdentity has been calculated for amino acids of dog and mouse sequences that are identical to human sequence (absent sequence, but
not extra sequences, in dog and mouse genes are included in the calculations).
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3.2. The canine BPAg2 mRNA co-migrates with the
human BPAg2 mRNA
By Northern blot hybridization, the human
BPAg2 cDNA probe hybridized a 6-kb band on
SCC 2/88 total RNA. This 6-kb band co-migrated
with a band from human keratinocyte total RNA
hybridized with the same human BPAg2 cDNA
probe (Fig. 3). These data indicate that human and
canine BPAg2 mRNA share similar molecular size.
3.3. The canine BPAg2 is localized in the upper skin
BMZ
By indirect immuno£uorescence studies, a rabbit
antibody raised against a 18-amino acid canine
NC16A domain peptide labeled the epidermal side
of the BMZ on salt-split normal canine skin, identi-
cal to the binding of a human BP patient’s anti-
BPAg2 autoantibodies; whereas a human epidermol-
ysis bullosa acquisita patient’s serum (with autoanti-
bodies against the anchoring ¢bril component type
VII collagen) labeled the dermal side of BMZ of
canine salt-split skin (Fig. 4). These data verify that
the isolated canine BPAg2 nucleotide sequence en-
codes a canine skin upper BMZ component. The
crossreaction of human BP autoantibodies with ca-
nine skin BMZ con¢rms the ¢ndings previously re-
ported [13,18] and suggests that the antigenic epi-
topes of human BPAg2 may be similar to that of
canine BPAg2.
3.4. The canine BPAg2 is localized to the upper
lamina lucida/hemidesmosome
Indirect immunoelectron microscopy localized hu-
man BP patient’s IgG anti-BPAg2 autoantibodies
binding sites exclusively to the upper lamina lucida/
hemidesmosomes of canine salt-split skin (Fig. 5).
No IgG was localized in the lower lamina lucida or
sublamina densa. Control normal human serum did
not show any IgG binding (data not shown). These
data indicate that the ultrastructural location of ca-
nine BPAg2 is identical to that of human BPAg2
[24].
3.5. The canine BPAg2 is a 180-kDa epidermal
protein
By immunoblotting, a rabbit antibody raised
against a canine NC16A peptide, but not the pre-
immune serum from the same rabbit, recognized a
Fig. 6. The canine BPAg2 is a 180-kDa epithelial protein. Im-
munoblot analysis of protein extracted from canine SCC 2/88
cells revealed that a 180-kDa protein (arrow) is labeled by a
rabbit antibody raised against an 18-amino acid canine NC16A
peptide, but not by the same dilution of pre-immune serum
from the same rabbit.
Fig. 5. The canine BPAg2 is ultrastructurally localized to the
upper lamina lucida/hemidesmosome. Indirect immunoelectron
microscopy performed on salt-split normal canine skin demon-
strated that a human BP patient’s IgG anti-BPAg2 autoanti-
bodies labeled the BMZ upper lamina lucida/hemidesmosomes
at the epidermal side (arrows). E, epidermis; D, dermis; LL,
lamina lucida space separated by salt; Scale bar: 1.0 Wm.
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180-kDa protein in the SCC 2/88 extracts (Fig. 6).
Thus, these data indicate that the canine BPAg2 has
a molecular size identical to that of human BPAg2
[4].
3.6. Canine BP patients’ autoantibodies recognized
the human antigenic NC16A epitopes
Fig. 7, upper panel, illustrates the results of ELI-
SA studies, demonstrating that two canine BP pa-
tients’ sera contained IgG autoantibodies recognizing
the human NC16A domain peptides (Table 2). The
IgG autoantibodies from canine patient 1 strongly
recognized peptide 1, minimally reacted with pepti-
des 2 and 4, but did not react with peptide 3. The
autoantibodies from canine patient 2 strongly recog-
nized peptide 2, moderately reacted with peptides 3
and 4, but did not react with peptide 1. The titer-
dependent speci¢city of the autoantibodies from ca-
nine patient 1 in recognizing peptide 1 is illustrated
in the lower panel of Fig. 7. Considering the rare
occurrence of canine BP, we may cautiously conclude
that the antigenic epitopes recognized by the canine
BP autoantibodies are very similar to the epitopes
recognized by human BP patients’ sera as previously
reported [6,7].
In this paper, we reported the isolation of a cDNA
encoding for part of the canine BPAg2 that was tar-
geted by autoantibodies from canine BP patients.
Sequence analyses of the deduced amino acids of
the canine NC16A domain revealed a low identity
with the human NC16A domain. However, we
showed that the antigenic epitopes, targeted by hu-
man BP autoantibodies, were also recognized by ca-
nine BP autoantibodies. With the antigenic epitopes
of canine BP autoantibodies delineated, we can now
move forward to develop a canine model of BP, in
the hope that we may be able to determine the pos-
sible role of eosinophils in the BP blister formation.
While the passive transfer experiments could delin-
eate the blistering process once the antibodies against
BPAg2 are formed, another important area in need
of exploration is what induces the autoantibody for-
mation in the ¢rst place. Study of the critical initiat-
ing factors in BP is at the present time hindered by
the lack of an active inducible animal model. The
cloning of the cDNA encoding for this disease-tar-
geted protein in dog may allow for the development
of an active inducible canine BP model. While the
inbred murine system provides an advantage of al-
lowing de¢ned immunogenetic analysis, the outbred
canine system provides a di¡erent advantage in that
it is clinically relevant to human disease ^ it is a true
Fig. 7. The canine BP autoantibodies recognized antigenic epi-
topes within the human NC16A domain. Upper panel is a Scat-
ter plot representation of ELISA results using four non-overlap-
ping synthetic peptides containing the entire human NC16A
domain (P1, P2, P3, P4). Canine patient 1 (a), canine patient 2
(O), or seven control sera (¢ve normal dogs, one dog a¡ected
with epidermolysis bullosa acquisita, and one dog a¡ected with
linear IgA bullous dermatosis) (b). Lower panel depicts the
titer-dependent speci¢c reactivity of autoantibodies from canine
patient 1 in recognizing peptide 1 of human NC16A. ELISA
plate immobilized with equal amount of synthetic peptide 1 was
incubated with increasing concentration of serum from canine
patient 1 (a) or six control sera (b) (four normal dog, one dog
each a¡ected with epidermolysis bullosa acquisita and linear
IgA bullous dermatosis). Each data point is an average of two
independent observations.
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re£ection of the outbred nature of human patient
population.
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